Want to see NTLA full AI Analyst Report?
NTLA Stock Chart & Stats
$13.51
-$0.37(-3.33%)
At close: 4:00 PM EDT
$13.51
-$0.37(-3.33%)
Day’s Range― - ―
52-Week Range$7.95 - $28.25
Previous CloseN/A
Volume3.46M
Average Volume (3M)3.29M
Market Cap
$1.67B
Enterprise Value$1.89K
Total Cash (Recent Filing)$437.76M
Total Debt (Recent Filing)$73.41M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding140,126,700
10 Day Avg. Volume2,909,400
30 Day Avg. Volume3,285,768
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.50Price Target Upside51.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.21
Revenue Forecast (FY)$50.26M
Bulls Say, Bears Say
Bulls Say
FDA Priority ReviewFDA acceptance and Priority Review materially advance lonvo-z toward commercialization and establish a defined regulatory timetable. If approved, the therapy could become the first in vivo CRISPR treatment and strengthen Intellia’s position in rare-disease gene editing.
Phase III EfficacyThe strong, statistically significant Phase III results demonstrate meaningful clinical benefit across the primary and key secondary endpoints. A one-time treatment that reduces attacks and ongoing therapy use could support durable adoption and differentiate lonvo-z from chronic prophylactic options.
Cash RunwayA substantial cash balance and stated runway into at least 2028 give Intellia time to complete regulatory work, prepare commercialization, and advance nex-z without immediate dependence on product revenue. This liquidity supports execution through important clinical and regulatory milestones.
Bears Say
Nex-z Liver SafetyThe nex-z liver enzyme signal creates a material development and regulatory risk for a major pipeline program. Continued monitoring, mitigation, and regulatory engagement may increase trial complexity, restrict eligible patients, or delay the path to approval and commercialization.
Persistent Cash BurnPersistent and worsening cash burn reflects the high cost of advancing Intellia’s clinical and commercial programs while revenue remains limited. Continued losses can erode financial flexibility over time and increase reliance on equity, debt, or collaboration funding before products generate sales.
Declining Collaboration RevenueThe sharp decline in collaboration revenue highlights the variability of Intellia’s current funding model, which depends on partner arrangements, reimbursements, and milestones rather than product sales. Lower partner-derived revenue increases pressure on cash reserves while internal programs remain in development.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $7.95 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.67B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 54 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 140,126,700 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 2.461%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (51.74% Upside)
$20.50 (51.74% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 68%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $135.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$20.50
▲(51.74% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.69% Insiders
15.31% Mutual Funds
34.30% Other Institutional Investors
19.05% Public Companies and Individual Investors